Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 16/20 | 0.47 |
| ▸ | PPARG | P37231 | 14/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3763317 | 0.94 | PPARA (0.41) | PPARAPPARG | |
| SCHEMBL3758770 | 0.93 | PPARA (0.42) | PPARAPPARGSMN1; SMN2 | |
| SCHEMBL3769108 | 0.92 | NPC1 (0.41) | PPARAPPARGNPC1RAB9A | |
| SCHEMBL3764480 | 0.92 | PPARA (0.46) | PPARAPPARG | |
| SCHEMBL3758105 | 0.92 | PPARA (0.38) | PPARAPPARGNPC1RAB9A | |
| SCHEMBL3764578 | 0.91 | PPARA (0.47) | PPARAPPARGLMNAHTTSMN1; SMN2 | |
| SCHEMBL3964743 | 0.91 | PPARA (0.38) | PPARAPPARG | |
| SCHEMBL3762603 | 0.90 | PPARA (0.39) | PPARAPPARGNPC1RAB9A | |
| SCHEMBL3763324 | 0.90 | PPARA (0.48) | PPARAPPARGL3MBTL1 | |
| SCHEMBL3763052 | 0.90 | PPARA (0.52) | PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268867-B2 | 1,3-dioxane carboxylic acids | CADILA HEALTHCARE LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-20100311795-A1 | 1,3-DIOXANE CARBOXYLIC ACIDS | CADILA HEALTHCARE LIMITED (IN) | 2010-12-09 | — | — | US | claimed |
| EP-1989192-B1 | 1,3-DIOXANE CARBOXYLIC ACIDS | CADILA HEALTHCARE LTD (IN) | 2009-07-22 | — | — | EP | claimed |
| US-8268867-B2 | 1,3-dioxane carboxylic acids | CADILA HEALTHCARE LIMITED (IN) | 2012-09-18 | — | — | US | disclosed |
| US-20100311795-A1 | 1,3-DIOXANE CARBOXYLIC ACIDS | CADILA HEALTHCARE LIMITED (IN) | 2010-12-09 | — | — | US | disclosed |
| EP-1989192-B1 | 1,3-DIOXANE CARBOXYLIC ACIDS | CADILA HEALTHCARE LTD (IN) | 2009-07-22 | — | — | EP | disclosed |
| EP-1989192-A2 | 1,3-DIOXANE CARBOXYLIC ACIDS | CADILA HEALTHCARE LTD. (IN) | 2008-11-12 | — | — | EP | disclosed |
| WO-2007099553-A2 | 1,3-DIOXANE CARBOXYLIC ACIDS | CADILA HEALTHCARE LIMITED (IN) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311795-A1 | 1,3-DIOXANE CARBOXYLIC ACIDS | SLC10A1, CYP11B2, UGT1A1 | PPARA 1132/4885PPARG 636/4885MAPK1 2627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.